Recent years have brought many changes to the market for non-surgical wrinkle treatments such as fillers and products 
made with botulinum toxin. The most recent changes include the introduction of lidocaine to popular hyaluronic acid fillers Juvederm and Restylane, and the announcements that several collagen-based fillers will be discontinued.
Both Allergan and Johnson & Johnson, announced that they will no longer produce their respective collagen products (the human-derived CosmoDerm and CosmoPlast, the bovine Zyderm and Zyplast for Allergan; the porcine Evolence for Johnson & Johnson).
For many years, collagen was the filler of choice for plastic surgeons and dermatologists. However, the hassle of skin allergy testing and the short-term results provided by these products made them inferior to the new fillers that are available today.
The popularity of non-animal hyaluronic acid (HA) dermal fillers (known as replacement fillers because they replace lost volume) and PLLA and PMMA fillers (known as stimulatory fillers because they stimulate collagen and fibroblast production) has been strong in the recent past. Products like Juvederm, Perlane, Restylane and Radiesse currently dominate the US market. Physicians says these fillers are simply more versatile, longer-lasting, bulkier, and better for deep-volume filling than collagen.
What will the world of fillers look like in the future? It’s difficult to say but change is certainly underway in the offices of plastic and cosmetic surgeons.
